Supplement Scholar
Metabolic / GLP-1

Retatrutide

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Retatrutide. Investigational triple agonist of GLP-1, GIP, and glucagon receptors with the largest weight-loss signal to date.

How it works. Activates GLP-1 and GIP receptors for insulin and satiety effects and additionally activates the glucagon receptor to increase energy expenditure and hepatic fat oxidation.

What the research supports. 2 graded claims. Strongest: Largest reported peptide-driven weight loss to date (preclinical).

Hormonal impact. Effects on Insulin, Glucagon signaling, GIP signaling, Leptin sensitivity.

Side effects and interactions. 1 medication interaction listed. Serious: Long-term safety still being studied.

Stacking. Pairs well with Comprehensive lifestyle program. Avoid combining with Personal or family history of MTC or MEN2.

Common forms. Available as Weekly subcutaneous injection (trial protocols).

Community. Experiences from people who have tried Retatrutide. Anecdotes are not medical advice.

Retatrutide. Investigational triple agonist of GLP-1, GIP, and glucagon receptors with the largest weight-loss signal to date.

No single structure

What it is

Retatrutide is a single-molecule triple agonist of GLP-1, GIP, and glucagon receptors, currently in late-stage trials.

Also called

LY3437943

How it works

Activates GLP-1 and GIP receptors for insulin and satiety effects and additionally activates the glucagon receptor to increase energy expenditure and hepatic fat oxidation.

Pathways

  • GLP-1, GIP, glucagon receptor agonism

Effects

  • ↓Body weight (largest documented for peptide therapy) decreases
  • ↑Resting energy expenditure increases
  • +Hepatic fat oxidation supports

What the research supports

Largest reported peptide-driven weight loss to datepreclinical
Improvements in MASLD/MASH markers in trialspreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑Insulinincreases
↑Glucagon signalingincreases
↑GIP signalingincreases
~Leptin sensitivitymodulates

Side effects & interactions

Common side effects

  • Nausea
  • Diarrhea
  • Increased heart rate

Serious

  • Long-term safety still being studied

Medication interactions

Insulin or sulfonylureasmoderate

Hypoglycemia risk.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Comprehensive lifestyle programCompounds metabolic benefits.

Avoid combining

  • Personal or family history of MTC or MEN2Class-shared contraindication.

Common forms

  • Weekly subcutaneous injection (trial protocols)

Discussion

Loading discussion…